Yunting Luo

发表

Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds.

W. Guida, Jie Wu, S. Sebti, 2008, Journal of medicinal chemistry.

Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation

Quentin Liu, Yunting Luo, D. Lin, 2016, Scientific Reports.

Synthesis and biological evaluation of aurora kinases inhibitors based on N-trisubstituted pyrimidine scaffold.

Quentin Liu, Zheng-chao Tu, Yunting Luo, 2018, European journal of medicinal chemistry.

Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors.

W. Guida, K. Daniel, S. Sebti, 2012, Journal of medicinal chemistry.

Effect of Ack1 tyrosine kinase inhibitor on ligand‐independent androgen receptor activity

D. Coppola, K. Mahajan, H. Lawrence, 2010, The Prostate.

Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting

F. Feng, K. Mahajan, J. Jez, 2022, Science Translational Medicine.

GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells.

U. Rix, G. Wright, E. Haura, 2014, ACS chemical biology.

Palladium-catalyzed Suzuki cross-coupling of N'-tosyl arylhydrazines.

Yunting Luo, Hui Yan, Jinbiao Liu, 2013, Chemical communications.

Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors.

Quentin Liu, Zheng-chao Tu, Yunting Luo, 2014, European journal of medicinal chemistry.

Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors.

Daniel N. Santiago, W. Guida, K. Daniel, 2010, Bioorganic & medicinal chemistry.

Synthesis and evaluation of new compounds bearing 3-(4-aminopiperidin-1-yl)methyl magnolol scaffold as anticancer agents for the treatment of non-small cell lung cancer via targeting autophagy.

Heying Pei, Lijuan Chen, A. Peng, 2020, European journal of medicinal chemistry.

A novel compound against oncogenic Aurora kinase A overcomes imatinib resistance in chronic myeloid leukemia cells.

Feimeng Zheng, Quentin Liu, Yunting Luo, 2015, International journal of oncology.

A Novel Small Molecule Aurora Kinase Inhibitor Attenuates Breast Tumor–Initiating Cells and Overcomes Drug Resistance

Feimeng Zheng, E. Lam, Quentin Liu, 2014, Molecular Cancer Therapeutics.

Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.

Huan Yang, J. Cheng, S. Sebti, 2012, Journal of medicinal chemistry.

A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A.

E. Schönbrunn, S. Sebti, Riazul Alam, 2012, ACS chemical biology.

Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.

U. Rix, A. Monteiro, G. Wright, 2016, Cell chemical biology.

Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition

U. Rix, K. Smalley, H. Lawrence, 2017, Molecular oncology.

Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation

Huan Yang, U. Rix, S. Sebti, 2014, Oncotarget.

Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112.

W. Guida, Yuan Ren, Jie Wu, 2010, Biochemical pharmacology.

Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.

U. Rix, A. Monteiro, G. Wright, 2017, ACS chemical biology.

Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.

K. Mahajan, H. Lawrence, N. Mahajan, 2015, Journal of medicinal chemistry.

The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors.

Michael S. Cohen, U. Rix, A. Monteiro, 2021, Cell chemical biology.